1. Home
  2. MP vs COGT Comparison

MP vs COGT Comparison

Compare MP & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MP Materials Corp.

MP

MP Materials Corp.

HOLD

Current Price

$59.39

Market Cap

7.4B

ML Signal

HOLD

Logo Cogent Biosciences Inc.

COGT

Cogent Biosciences Inc.

HOLD

Current Price

$37.89

Market Cap

6.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MP
COGT
Founded
2017
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Mining
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.4B
6.6B
IPO Year
2020
2018

Fundamental Metrics

Financial Performance
Metric
MP
COGT
Price
$59.39
$37.89
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
13
15
Target Price
$75.25
$36.21
AVG Volume (30 Days)
6.9M
1.9M
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
12.28
N/A
EPS
N/A
N/A
Revenue
$331,952,000.00
$7,871,000.00
Revenue This Year
$100.51
N/A
Revenue Next Year
$60.41
$1,733.58
P/E Ratio
N/A
N/A
Revenue Growth
147.15
N/A
52 Week Low
$37.81
$11.53
52 Week High
$100.25
$43.73

Technical Indicators

Market Signals
Indicator
MP
COGT
Relative Strength Index (RSI) 67.78 43.90
Support Level $51.86 $36.53
Resistance Level $64.62 $40.99
Average True Range (ATR) 3.09 2.06
MACD 1.99 -0.53
Stochastic Oscillator 91.33 16.72

Price Performance

Historical Comparison
MP
COGT

About MP MP Materials Corp.

MP Materials Corp is the producer of rare earth materials in the Western Hemisphere. The company owns and operates the Mountain Pass Rare Earth Mine and Processing Facility, the only rare earth mining and processing site of scale in North America. The company is also developing a rare earth metal, alloy, and magnet manufacturing facility in Fort Worth, Texas. The company's operations are organized into two reportable segments: Materials and Magnetics.

About COGT Cogent Biosciences Inc.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

Share on Social Networks: